Singapore markets closed
Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,203.32 +31.17 (+0.38%) Bitcoin USD
61,601.40 +3,223.41 (+5.52%) CMC Crypto 200
1,325.37 +48.39 (+3.79%)
Prothena Corporation plc (PRTA)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 09:54AM EDT. Market open.
| Previous close | 22.04 |
| Open | 22.99 |
| Bid | 23.24 x 200 |
| Ask | 23.60 x 200 |
| Day's range | 22.86 - 23.52 |
| 52-week range | 19.65 - 79.65 |
| Volume | |
| Avg. volume | 626,303 |
| Market cap | 1.258B |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.76 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 66.77 |
Business WireProthena to Report First Quarter 2024 Financial Results on May 8
DUBLIN, Ireland, May 01, 2024--Prothena announced that it will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets.
ZacksEarnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireProthena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
DUBLIN, April 15, 2024--Prothena today announced a publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab.
© 2024 Yahoo. All rights reserved.